Victoza Caused Side Effects in 80% of Children, But Helped Them Lose Weight: Study
Most of the adverse events were gastrointestinal in nature, mirroring claims being raised in thousands of Ozempic lawsuits filed over stomach paralysis and ileus.
Tag Archives: Weight Loss
-
-
GLP-1 Drug Prescriptions Have Doubled in Recent Years, But Many Users Quit Soon After Starting
Use of Ozempic, Wegovy, Mounjaro and other GLP-1 drugs has spiked in recent years due to their effectiveness promoting weight loss, but side effects often cause users to discontinue the treatment within the first year.
-
Vision Problems From Ozempic, Other GLP-1 Drugs May Result From Rapid Correction of Hyperglycemia: Study
Researchers say it may be impossible to establish a causal link between Mounjaro, Ozempic and vision loss problems.
-
GLP-1 Lawsuit Defendants Filed Motion To Dismiss Most Claims in Plaintiffs’ Master Complaint
Drug makers hope to defeat failure to warn charges during hearings over certain cross-cutting issues, later in the GLP-1 litigation.
-
Side Effects of Ozempic, Other GLP-1 Drugs Are Mixed, With Net Benefits Overall: Study
Researchers found that GLP-1 drugs benefit those with diabetes or obesity, but more than double the risk of acute pancreatitis and cause other side effects.
-
Evidentiary Hearing for “Cross Cutting” Ozempic Lawsuit Causation Issues Scheduled for May 2025
The extensive pretrial proceedings mean the first Ozempic bellwether trials are unlikely to begin until at least 2026 or 2027.
-
EU Launches Investigation Into Ozempic Vision Loss Problems
Following the publication of recent studies, Danish health experts warn that they have received 19 reports of vision problems from Ozempic or Wegovy since July.
-
Ozempic NAION Vision Loss Risks Confirmed in Another Study
Findings are similar to those discovered by Harvard researchers in an Ozempic vision loss study published last summer.
-
MDL Judge Schedules Ozempic Lawsuit Status Conferences Throughout 2025
With the first Ozempic lawsuit bellwether trials not expected to begin until at least late 2026 or early 2027, the court will address motions to dismiss and other “cross cutting” issues in 2025.
-
Ozempic Ileus Lawsuit Filed by Woman Left With Gastrointestinal Problems After Receiving Injections for 2 Years
Lawsuit claims Novo Nordisk's failures to warn about the risk of gastroparesis and Ileus from Ozempic were "wanton, willful, fraudulent, reckless acts."
